⚠️
Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Influenza virus test negative
3,552 total reports25.5% serious outcomes
Share
3,552
Total Reports
70
Deaths
836
Hospitalizations
25.5
Severity Rate
% serious outcomes
About Influenza virus test negative Reports
Influenza virus test negative has been reported 3,552 times in VAERS from 1990 to 2026.
Of these reports, 70 were associated with death (1.97%) and 836 involved hospitalization.
The overall serious outcome rate (death or hospitalization) for reports mentioning Influenza virus test negative is 25.5%.
Understanding Influenza virus test negative in VAERS
•Temporal association only: These reports show Influenza virus test negative occurred after vaccination, not necessarily because of vaccination.
•Background rates matter: Many symptoms occur naturally at baseline rates in the population, unrelated to vaccination.
•Reporting variability: Medical terminology may be used differently by various healthcare providers and over time.
•Investigation needed: High-frequency reports may trigger further epidemiological studies to determine causation.
What This Data Shows
Most Associated Vaccines: The vaccines most frequently mentioned in reports with Influenza virus test negative. This may reflect usage patterns, not causation.
Severity Patterns: The percentage of reports that involve serious outcomes can help prioritize safety investigations.
Reporting Trends: Changes in reporting frequency over time may reflect increased awareness, media attention, or actual safety signals.
Most Associated Vaccines
1. COVID192,128
2. COVID19-2350
3. FLU4258
4. PNC13227
5. FLU3199
6. MMR179
7. VARZOS151
8. HEPA137
9. PPV134
10. HIBV127
Quick Facts
Reports:3,552
Deaths:70
Hospitalizations:836
Mortality Rate:1.97%
Severity Rate:25.5%
Related Analysis
Explore Further
Data Source
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.